RPS6KA2 and ovarian cancer: Consistent with this, CCK8 analysis demonstrated that, upon exposure to different concentrations of cisplatin, ovarian cancer cells with low RPS6KA2 expression displayed enhanced cell viability, whereas those with high RPS6KA2 expression showed greater sensitivity and reduced survival (Fig. 2D).